表决情况：3 票同意，0 票反对，0 票弃权。通过本议案。 监事会认为，公司本次以自有资金参与设立华润医药产业投资基金二期暨 关联交易事项符合公司战略发展规划，不会对公司财务及经营状况产生重大不 利影响。本次关联交易的审议及决策程序合法合规，不存在损害公司及股东、 特别是中小股东利益的情形。监事会同意公司参与设立华润医药产业投资基金 二期暨关联交易的事项。 特此公告。 证券代码：600750 证券简称：江中药业 公告编号：2025-036 江中药业股份有限公司 第十届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 江中药业股份有限公司（以下简称"公司"）第十届监事会第六次会议于 2025 年 7 月 16 日在公司会议室以现场结合视频方式召开，会议通知于 2025 年 7 月 11 日以书面形式发出，应参会监事 3 人，实到 3 人。会议召集召开符合 《公司法》和《公司章程》的有关规定。 会议由监事会主席周娇女士主持，经与会监事认真讨论，审议通过以下议 案： 一、关于参与设立华润医药产业投资基金 ...

Core Insights - The report indicates that over 150 million people in China suffer from liver-related issues such as fatty liver and hepatitis, with 80% of early liver damage showing no obvious symptoms [1][2][5] - The rising awareness of health management has led to a diversified demand for health products, particularly liver health products, which are gaining traction among younger consumers [1][2][4] - The liver health market in China is projected to exceed 80 billion yuan this year, positioning it as a star segment within the broader health market [5] Market Trends - The liver health product market has been experiencing rapid growth since 2012, driven by core demands such as metabolism promotion, dietary regulation, and improvement of physical and mental states [4][6] - The demographic of liver health product consumers is shifting, with 35% of consumers in 2023 aged between 26 and 35, making this age group the largest and fastest-growing segment [4][6] Product Offerings - Various forms of liver health products are emerging, including liver tea, liver protection tablets, liver capsules, and health-enhanced gummies, catering to different age groups and health conditions [6] - Natural ingredient-rich liver health products are particularly favored by consumers [4] Sales Channels - Traditional direct sales are declining, with pharmacies, shopping malls, and online platforms becoming the primary purchasing channels, especially e-commerce, which is expected to continue growing due to the younger generation's health consciousness [6][7] - Local brands are achieving significant sales, with some health products surpassing 500 million yuan in annual sales [7]

Core Viewpoint - Jiangzhong Pharmaceutical Co., Ltd. announced a cash dividend of 0.7 yuan per share, totaling approximately 444.5 million yuan, to be distributed to shareholders on June 20, 2025 [1][5]. Dividend Distribution Plan - The cash dividend distribution is based on a total share capital of 634,996,022 shares, with a total cash dividend payout of 444,497,215.4 yuan [1]. - The key dates for the dividend distribution are as follows: - Record date: June 19, 2025 - Ex-dividend date: June 20, 2025 - Cash dividend payment date: June 20, 2025 [1]. Taxation on Dividends - For individual shareholders holding shares for more than one year, the dividend income is exempt from personal income tax [3][4]. - For shares held between one month and one year, a tax of 0.07 yuan per share will be deducted, while shares held for one month or less will incur a tax of 0.14 yuan per share [4]. - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net cash dividend of 0.63 yuan per share [4][5]. Contact Information - For inquiries regarding the dividend distribution plan, shareholders can contact the company's investment securities department at 0791-88169323 [5].

证券代码：600750 证券简称：江中药业 公告编号：2025-035 江中药业股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 3. 分配方案： 本次利润分配以方案实施前的公司总股本634,996,022股为基数，每股派发现 金红利0.7元（含税），共计派发现金红利444,497,215.4元。 三、相关日期 每股分配比例 A 股每股现金红利0.7元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/19 | － | 2025/6/20 | 2025/6/20 | 差异化分红送转： 否 一、通过分配方案的股东大会届次和日期 本次利润分配方案经江中药业股份有限公司（以下简称"公司"）2025 年 5 月 16 日的2024年年度股东大会审议通过。 二、分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公 ...

Core Points - The company has completed the initial grant registration of its second phase restricted stock incentive plan, granting 6,128,000 shares at a price of 13.70 yuan per share to 165 eligible participants [1][2][5] - The plan's effective period lasts up to 120 months, with a lock-up period of 24, 36, and 48 months for the granted shares [7][8] - The total subscription amount received from the participants is 83,953,600 yuan, which will be used to supplement the company's working capital [15][17] Grant Details - The initial grant date was set for May 16, 2025, with the actual number of shares granted adjusted to 6,128,000 due to three participants voluntarily giving up their shares [2][5] - The stock source is from the company's directed issuance of A-share common stock [3] - The registration of the granted shares was completed on June 6, 2025 [15] Lock-up and Release Conditions - The lock-up period for the granted shares is divided into three phases, with restrictions on transfer, collateral use, or debt repayment during this time [8] - The release of the shares is contingent upon meeting specific performance conditions at both the company and individual levels over the assessment period from 2025 to 2027 [12][14] Financial Impact - The company will recognize the cost of the stock grants based on the fair value determined at the grant date, impacting its financial statements [16][17] - The total share capital will increase by 6,128,000 shares, leading to a dilution of the controlling shareholder's stake from 43.25% to 42.84% without affecting control [15][17]

证券代码：600750 证券简称：江中药业 公告编号：2025-034 江中药业股份有限公司 关于第二期限制性股票激励计划首次授予结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 根据中国证券监督管理委员会《上市公司股权激励管理办法》、上海证券交 易所、中国证券登记结算有限责任公司上海分公司的有关规定，江中药业股份有 限公司（以下简称"公司"）已完成公司第二期限制性股票激励计划（以下简称 "本激励计划"）的首次授予登记工作，有关具体情况如下： 一、本激励计划首次授予情况 公司于 2025 年 5 月 16 日召开第十届董事会第五次会议和第十届监事会第五 次会议，审议通过了《关于江中药业第二期限制性股票激励计划向激励对象首次 授予限制性股票的议案》，确定本激励计划的首次授予日为 2025 年 5 月 16 日， 向符合条件的 168 名激励对象授予 621.7 万股限制性股票，授予价格为 13.70 元 /股。公司薪酬与考核委员会已事前审议通过该议案，监事会同意该议案并出具 了核查意见。 在确定授予 ...

证券代码：600750 证券简称：江中药业 公告编号：2025-033 江中药业股份有限公司 关于 2021 年限制性股票激励计划预留授予部分 第二个解除限售期解锁暨上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 139,938股。 本次股票上市流通总数为139,938股。 本次股票上市流通日期为2025 年 5 月 30 日。 江中药业股份有限公司（以下简称"公司"）第十届董事会第四次会议和第十 届监事会第四次会议审议通过了《关于公司 2021 年限制性股票激励计划预留授予 部分第二个解锁期解锁条件成就的议案》。根据《2021 年限制性股票激励计划（2022 年 11 月修订稿）》（以下简称"激励计划"）的有关规定和公司 2021 年第二次临时 股东大会的授权，公司董事会认为公司激励计划规定的预留授予部分限制性股票 第二个解除限售期解除限售条件已经成就。具体内容详见 2025 年 4 月 26 日公司 刊登于上海证券报、中国证券报 ...

Core Points - The company announced the repurchase and cancellation of restricted stocks due to five incentive targets no longer meeting the criteria of the 2021 stock incentive plan [1][2] - A total of 149,602 restricted stocks will be repurchased and canceled, leaving 1,715,544 restricted stocks remaining under the incentive plan [2][3] - The repurchase is expected to be completed by May 23, 2025, with necessary legal and registration procedures to follow [3][4] Summary by Sections Repurchase and Cancellation Reasons - The repurchase and cancellation of restricted stocks are based on the non-compliance of five incentive targets due to reasons such as job transfer, retirement, and resignation [2][4] Repurchase Details - The decision for the repurchase was approved in the board meetings held on March 18, 2025, and the legal opinion was obtained [1][4] - The company has opened a special securities account for the repurchase with the China Securities Depository and Clearing Corporation [3] Company Commitments - The board assures that the decision-making process and information disclosure comply with relevant laws and regulations, ensuring no harm to the rights of incentive targets or creditors [4][5] - The company commits to handling any legal responsibilities arising from disputes related to the repurchase [4]

证券代码：600750 证券简称：江中药业 公告编号：2025-032 江中药业股份有限公司 股权激励限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 回购注销原因：江中药业股份有限公司（以下简称"公司"）2021 年限 制性股票激励计划中，5 名激励对象因不再符合股权激励计划中有关激励对象 的规定，公司对前述激励对象相关已授予但尚未解除限售的限制性股票进行回 购注销。 本次注销股份的有关情况 | 回购股份数（股） | 注销股份数量（股） | 注销日期 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 149,602 | 149,602 | 2025 5 | 年 | 月 | 23 | 日 | 一、本次限制性股票回购注销的决策与信息披露 1、2025 年 3 月 18 日，第十届董事会第三次会议和第十届监事会第三次会 议，审议通过了《关于回购注销部分激励对象已获授但尚未解除限售的限制性 股票及调整回购价格的议案》。公司聘 ...

国浩律师（上海）事务所 关 于 江中药业股份有限公司 2021 年限制性股票激励计划 部分限制性股票回购注销实施 的 法律意见书 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China T. +86 21 52341668 F. +86 21 52341670 E. grandallsh@grandall.com.cn W. www.grandall.com.cn 2025 年 5 月 | 释 义 | | | 2 | | --- | --- | --- | --- | | 第一节 | 律师声明事项 | | 4 | | 第二节 | 正文 | | 5 | | | | 一、本次回购注销的批准与授权 | 5 | | | | 二、本次回购注销的具体情况 | 10 | | 三、结论意见 | | | 12 | 国浩律师（上海）事务所 法律意见书 释 义 国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 关于江中药业股份有限公司 以下词 ...